van Ballegoij Wouter J C, van de Stadt Stephanie I W, Huffnagel Irene C, Kemp Stephan, van der Knaap Marjo S, Engelen Marc
Department of Pediatric Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
Department of Neurology, OLVG Hospital, Amsterdam, Netherlands.
Front Physiol. 2020 Jul 17;11:786. doi: 10.3389/fphys.2020.00786. eCollection 2020.
Myelopathy is the core clinical manifestation of adrenoleukodystrophy (ALD), which is the most common peroxisomal disorder. Development of therapies requires sensitive and clinically relevant outcome measures. Together with spastic paraparesis, balance disturbance is the main cause of disability from myelopathy in ALD. In this cross-sectional study, we evaluated whether postural body sway - a measure of balance - could serve as a surrogate outcome in clinical trials.
Forty-eight male ALD patients and 49 age-matched healthy male controls were included in this study. We compared sway amplitude and sway path of ALD patients to controls. We then correlated the body sway parameters showing the largest between-group differences with clinical measures of severity of myelopathy. To correct for age, we performed multiple linear regression analysis with age and severity of myelopathy as independent variables.
All body sway parameters were significantly higher in patients than in controls, with medium to large effect sizes ( = 0.43-0.66, < 0.001). In the subgroup of asymptomatic patients, body sway amplitude was also higher, but the difference with controls was smaller than for symptomatic patients (effect size = 0.38-0.46). We found moderate to strong correlations between body sway amplitude and clinical severity of myelopathy ( = 0.40-0.79, < 0.005). After correction for age, severity of myelopathy was a significant predictor of body sway amplitude in all regression models.
These results indicate that postural body sway may serve as a surrogate outcome for myelopathy in ALD. Such outcomes are important to evaluate new therapies in clinical trials. Further longitudinal studies are needed and ongoing in this cohort.
脊髓病是肾上腺脑白质营养不良(ALD)的核心临床表现,ALD是最常见的过氧化物酶体疾病。开发治疗方法需要敏感且与临床相关的疗效指标。与痉挛性截瘫一起,平衡障碍是ALD脊髓病导致残疾的主要原因。在这项横断面研究中,我们评估了姿势性身体摆动(一种平衡指标)是否可作为临床试验中的替代结局指标。
本研究纳入了48名男性ALD患者和49名年龄匹配的健康男性对照。我们比较了ALD患者与对照的摆动幅度和摆动路径。然后,我们将组间差异最大的身体摆动参数与脊髓病严重程度的临床指标进行关联。为校正年龄,我们以年龄和脊髓病严重程度作为自变量进行多元线性回归分析。
患者的所有身体摆动参数均显著高于对照,效应量为中等至大(= 0.43 - 0.66,< 0.001)。在无症状患者亚组中,身体摆动幅度也较高,但与对照的差异小于有症状患者(效应量 = 0.38 - 0.46)。我们发现身体摆动幅度与脊髓病临床严重程度之间存在中度至强相关性(= 0.40 - 0.79,< 0.005)。校正年龄后,在所有回归模型中,脊髓病严重程度都是身体摆动幅度的显著预测因素。
这些结果表明,姿势性身体摆动可能作为ALD脊髓病的替代结局指标。此类结局指标对于评估临床试验中的新疗法很重要。该队列需要并正在进行进一步的纵向研究。